Skip to content
EntityQ5333851· pop 5· linked from 602 articles

Ecopipam (development codes SCH-39166, EBS-101, and PSYRX-101) is a dopamine antagonist which is under development for the treatment of Lesch–Nyhan syndrome, Tourette syndrome, speech disorders, and restless legs syndrome. It is taken by mouth.

Wikidata facts

Mass
313.123
Show 4 more facts
chemical formula
C₁₉H₂₀ClNO
isomeric SMILES
CN1CCC2=CC(=C(C=C2[C@@H]3[C@@H]1CCC4=CC=CC=C34)O)Cl
canonical SMILES
CN1CCC2=CC(=C(C=C2C3C1CCC4=CC=CC=C34)O)Cl
Commons category
Ecopipam
Sources (2)

via Wikidata · CC0

~4 min read

Article

6 sections
Contents
  • Pharmacology
  • Pharmacodynamics
  • Research
  • Chemistry
  • See also
  • References

Ecopipam (development codes SCH-39166, EBS-101, and PSYRX-101) is a dopamine antagonist which is under development for the treatment of Lesch–Nyhan syndrome, Tourette syndrome, speech disorders, and restless legs syndrome. It is taken by mouth.

Ecopipam acts as a selective dopamine D1 and D5 receptor antagonist. It is orally active, has an elimination half-life of 10hours, crosses the blood–brain barrier, and substantially occupies brain dopamine receptors. Side effects of ecopipam may include depression, anxiety, fatigue, sedation, somnolence, insomnia, headaches, muscle twitching, and suicidal ideation, among others. It appears to lack the typical extrapyramidal effects like tardive dyskinesia that occur with D2 receptor antagonists.

Available in 4 languages

via Wikidata sitelinks · CC0

Connections

Categories